[Immunosuppressive treatment of Behçet's syndrome. Long-term results].
We present middle and long-term results of cyclophosphamide and procarbazine therapy of Behçet's uveitis. Of 45 patients, 20 were followed for 1-4 years (14 successful cases, 5 satisfactory results with regression of inflammatory signs but no functional improvement, 1 failure), 17 for 5-10 years (9 successes, 5 satisfactory results, 3 failures), and 8 for 11-16 years (2 successes, 2 satisfactory results, 4 failures). The high percentage of success (over 55%) could be attributed partly to the early onset of therapy and may be partly to the choice of drugs.
Martenet
A C
AC
Paccolat
F
F
D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011344:Procarbazine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014605:Uveitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects
D011344:Procarbazine; D003520:Cyclophosphamide
Traitement immunodépresseur du syndrome de Behçet. Résultats à long terme.